mRNA Test Screens for Multiple Cancers from Single Blood Sample

A late stage cancer diagnosis can be attributed to many factors such as postponing cancer screening, the fact that symptoms often don't appear until cancer has progressed, or a lack of convenient screening options. Now, a new blood test that detects the molecular signatures of multiple cancers from a single sample of blood could help find cancer earlier.

StageZero Life Sciences, Ltd. (Richmond Hill, Canada) next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The Aristotle test works by interrogating mRNA from a sample of whole blood and detecting gene expression profiles indicative of specific cancers. It screens for the molecular signatures associated with multiple, individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach, prostate, and others.

"Far too often, cancer is diagnosed and treated at a late stage, which can dramatically decrease survival rates and affect patients' quality of life," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "This is more of an issue now, with the COVID-19 pandemic having significantly reduced patient/physician interactions. We are seeing a wave of late-stage diagnoses" he continued. "Use of a blood test that looks for the most common forms of treatable cancers can help reduce the risk of developing advanced-stage cancer through early detection. We believe that providing an opportunity to find cancer early will facilitate more favorable outcomes."

Related Links:
StageZero Life Sciences, Ltd.